Compare Quest Diagnostics Inc (DGX) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Icl Group Ltd — how do they compare? Quest Diagnostics Inc trades at $237.62 (market cap $26.21B), while Icl Group Ltd trades at $5.46 (market cap $6.94B). The key difference: Quest Diagnostics Inc is far larger — about 3.8× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| DGX | ICL | |
|---|---|---|
Market Cap | $26.21B | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $238.50 | $6.84 |
52-Week Low | $173.49 | $4.80 |
Enterprise Value | $31.97B | $9.58B |
Dividend Yield | 1.45% | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
ICL trades at $5.455, up 2.15% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.12 per share, beating estimates, and announced a cost-transformation program. Revenue for 2025 was $7.15 billion, with a net income margin of 3.95%. The stock has a P/E ratio of 22.25 and an EV/EBITDA of 7.02.
Outlook is mixed; earnings beats and operational improvements support upside, but analyst consensus is entirely Hold, reflecting valuation concerns. Key risks include raw material cost volatility and foreign exchange headwinds. The stock offers a dividend yield but faces margin pressure from declining profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
